Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSO-LONG: Enstilar Maintenance for Psoriasis
NCT02899962Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in Psoriasis vulgaris (PV) comparing Enstilar Maintenance with Vehicle Maintenance (2 arms). Primary endpoint: Time to First Relapse at Week 56. Started Feb 2017; status: completed.
02
Drugs
calcipotriol
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02899962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899962.